Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
Animals
Antibody-Dependent Cell Cytotoxicity
/ drug effects
Antineoplastic Agents, Immunological
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
CTLA-4 Antigen
/ antagonists & inhibitors
Cancer Vaccines
/ immunology
Humans
Mice
Mice, Inbred BALB C
Neoplasms
/ immunology
T-Lymphocytes, Regulatory
/ metabolism
CTLA-4
FOXP3
antibody-dependent cell-mediated cytotoxicity
cancer immunotherapy
regulatory T cells
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
08 01 2019
08 01 2019
Historique:
pubmed:
28
12
2018
medline:
13
3
2019
entrez:
28
12
2018
Statut:
ppublish
Résumé
Anti-CTLA-4 mAb is efficacious in enhancing tumor immunity in humans. CTLA-4 is expressed by conventional T cells upon activation and by naturally occurring FOXP3
Identifiants
pubmed: 30587582
pii: 1812186116
doi: 10.1073/pnas.1812186116
pmc: PMC6329979
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
CTLA-4 Antigen
0
CTLA4 protein, human
0
Cancer Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
609-618Déclaration de conflit d'intérêts
Conflict of interest statement: H.N. received a research grant from Bristol Myers Squibb. S.S. received a research grant from Chugai Pharmaceutical Co., Ltd. T.K. is employed by Chugai Pharmaceutical Co., Ltd. which provided some of the antibodies used in this study.
Références
Immunity. 2002 Jan;16(1):23-35
pubmed: 11825563
Nat Rev Immunol. 2011 Nov 25;11(12):852-63
pubmed: 22116087
J Immunol. 1999 Nov 15;163(10):5211-8
pubmed: 10553041
Nat Rev Immunol. 2008 Jan;8(1):34-47
pubmed: 18064051
Cancer Cell. 2018 Apr 9;33(4):649-663.e4
pubmed: 29576375
Cancer. 2006 Dec 15;107(12):2866-72
pubmed: 17099880
Science. 2008 Oct 10;322(5899):271-5
pubmed: 18845758
Clin Cancer Res. 2003 Feb;9(2):606-12
pubmed: 12576425
Immunol Cell Biol. 2014 Jul;92(6):475-80
pubmed: 24732076
Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):E6400-E6409
pubmed: 28698369
Clin Cancer Res. 2012 Apr 1;18(7):2039-47
pubmed: 22271879
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17945-50
pubmed: 24127572
Immunity. 2009 Jun 19;30(6):899-911
pubmed: 19464196
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Cancer Immunol Res. 2013 Jul;1(1):32-42
pubmed: 24777248
J Exp Med. 2005 Oct 3;202(7):885-91
pubmed: 16186187
Cell Res. 2017 Jan;27(1):109-118
pubmed: 27995907
Science. 2014 Dec 19;346(6216):1536-40
pubmed: 25525252
J Exp Med. 2013 Aug 26;210(9):1685-93
pubmed: 23897982
Immunity. 2017 Apr 18;46(4):577-586
pubmed: 28410988
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
MAbs. 2013 Mar-Apr;5(2):229-36
pubmed: 23406628
Immunity. 2009 May;30(5):636-45
pubmed: 19464986
Proc Natl Acad Sci U S A. 2015 May 12;112(19):6140-5
pubmed: 25918390
J Immunol. 2015 Feb 15;194(4):2022-31
pubmed: 25609839
J Clin Invest. 2006 Jul;116(7):1935-45
pubmed: 16778987
Sci Rep. 2015 Oct 14;5:15179
pubmed: 26462617
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
Nat Med. 2016 Jun;22(6):679-84
pubmed: 27111280
J Exp Med. 2013 Aug 26;210(9):1695-710
pubmed: 23897981
Nat Rev Immunol. 2006 Apr;6(4):295-307
pubmed: 16557261
Adv Cancer Res. 2006;95:1-30
pubmed: 16860654
Immunity. 1996 Jun;4(6):535-43
pubmed: 8673700
Science. 2011 Apr 29;332(6029):600-3
pubmed: 21474713
Annu Rev Immunol. 2004;22:531-62
pubmed: 15032588